Patents by Inventor John DiMaio
John DiMaio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140323420Abstract: Described herein are compositions and methods for treating or preventing a sexually transmitted infection in a subjectType: ApplicationFiled: November 8, 2012Publication date: October 30, 2014Inventors: Stephen Dewhurst, David Easterhoff, Brad Nilsson, John Dimaio, Alan Smrcka, Jerry Yang, Christina Capule
-
Publication number: 20090163933Abstract: An ear hair removal instrument including a head, at least a portion of which its outer surface is covered with cold wax. The head is shaped and sized to be receivable in the outer ear while preventing insertion into the middle ear. A handle is mounted at its distal end to the head. In use, the head of the instrument is inserted in the outer ear so that the cold wax disposed on the head comes into contact with the ear hair. While disposed in the outer ear, the ear hair in contact with the cold wax is extracted from its follicles by simultaneously rotating and pulling the instrument.Type: ApplicationFiled: December 20, 2007Publication date: June 25, 2009Inventor: John DiMaio
-
Publication number: 20030032774Abstract: This invention relates to opioid peptides, to pharmaceutical compositions containing the peptides, and to methods for controlling pain by administering the peptides or pharmaceutical compositions. The peptides have a high degree of selectivity for the &mgr;-opioid receptor. Although they are highly lipophilic, the peptides do not readily cross the blood brain barrier (BBB). Because the peptides act peripherally, they substantially avoid the side effects associated with central analgesic action.Type: ApplicationFiled: November 26, 2001Publication date: February 13, 2003Applicant: AstraZeneca ABInventors: William Brown, John DiMaio, Peter Schiller, Rene Martel, Francis Martel, Diane Martel, Pierre Martel
-
Patent number: 6060451Abstract: A thrombin inhibitor comprising a first bulky hydrophobic portion interacting with the catalytic site of thrombin responsible for proteolysis and a second portion at least maintaining the hydrophobic and acidic character of amino acids 55 to 60 of native hirudin at the C-terminal non-catalytic region of N-acetyl-hirudin45-65. Between the first and second portions is a divalent linker moiety having a chain length of at least 10 carbon atoms. Connecting the first bulky hydrophobic portion and the linker is a peptidomimetic bond. Preferably, the bulky hydrophobic portion comprises at least one amino acid of D-configuration. The compounds are useful in the treatment of thrombotic disorders.Type: GrantFiled: March 20, 1995Date of Patent: May 9, 2000Assignee: The National Research Council of CanadaInventors: John DiMaio, Yasuo Konishi, Feng Ni, Torsten Steinmetzer
-
Patent number: 6057314Abstract: This invention relates to the discovery of heterocyclic competitive inhibitors of the enzyme thrombin, their preparation, and pharmaceutical compositions thereof. As well, this invention relates to the use of such compounds and compositions in vitro as anticoagulants and in vivo as agents for the treatment and prophylaxis of thrombotic disorders such as venous thrombosis, pulmonary embolism and arterial thrombosis resulting in acute ischemic events such as myocardial infarction or cerebral infarction. Moreover, these compounds and compositions have therapeutic utility for the prevention and treatment of coagulopathies associated with coronary bypass operations as well as restenotic events following transluminal angioplasty.Type: GrantFiled: June 23, 1997Date of Patent: May 2, 2000Assignee: Biochem Pharma Inc.Inventors: John Dimaio, M. Arshad Siddiqui, John W. Gillard, Yves St-Denis, Micheline Tarazi, Patrice Preville, Sophie Levesque, Benoit Bachand, Annette Marian Doherty, Jeremy John Edmunds
-
Patent number: 6054474Abstract: Polycyclic alkaloids of formula (I), ##STR1## wherein R.sub.1 is H, C.sub.1-6 alkyl, or C.sub.6-12 aryl optionally substituted with polar groups; R.sub.2 and R.sub.3 are independently H, OH, C.sub.1-6 alkyl, --C(NH)--NH.sub.2, a positively charged group, or C.sub.7-13 aralkyl optionally substituted with NH.sub.2, OH, C.sub.1-6 alkyl, or halogen; or R.sub.2 and R.sub.3 together form a 5 to 6 member ring optionally incorporating a heteroatom; R.sub.4 is H, C.sub.1-6 alkyl, OR.sub.6, SR.sub.6 or N(R.sub.6).sub.2, wherein each R.sub.6 is independently H, C.sub.1-3 alkyl; X is O, S, SO, SO.sub.2, N--R.sub.5, or C--(R.sub.5).sub.2, wherein each R.sub.5 is independently H, C.sub.1-6 alkyl, or C.sub.7-13 aralkyl optionally interrupted with one or more heteroatom; n is an integer from 0 to 2; m is an integer from 0 to 3; with the proviso that when X is CH.sub.2 then R1 is not CH.sub.3, R.sub.2 and R.sub.3 are not both H, R.sub.4 is not OH, m is not 3 and n is not 0.Type: GrantFiled: March 25, 1998Date of Patent: April 25, 2000Assignee: Biochem Pharma, Inc.Inventors: John Dimaio, Dilip M. Dixit
-
Patent number: 6034097Abstract: The present invention is directed to compounds that act as analgesics and that have the structure of formula (I): ##STR1## wherein; Z is ##STR2## wherein, n is 1 or 2, and R.sub.0 is C.sub.6-12 aryl or C.sub.7-8 aralkyl; orR.sub.1 is selected from the group consisting of hydrogen; --NH--C.sub.1-6 alkyl; C.sub.1-6 alkyl; C.sub.6-12 aryl; C.sub.7-18 aralkyl; arginyl; and R.sub.30 NHC(.dbd.NH)--, wherein R.sub.30 is hydrogen, C.sub.6-12 aryl, C.sub.7-18 aralkyl, or C.sub.1-6 alkyl;R.sub.2 is hydrogen; C.sub.1-6 alkyl; or OH;R.sub.3 is C.sub.6-12 aryl; C.sub.7-18 aralkyl; --CH.sub.2 --C.sub.6 H.sub.2 R.sub.8 R.sub.9 ;or --CH.sub.2 --OHC.sub.6 HR.sub.8 R.sub.9, wherein each of R.sub.8 and R.sub.9 is independently, or hydrogen;R.sub.4 C.sub.6-12 aryl; C.sub.7-18 aralkyl; C.sub.1-12 alkyl; or a substituted or unsubstituted cyclohexyl;R.sub.5 is C.sub.1-6 alkyl; hydrogen; OH; halogen; SH; NO.sub.2 ; NH.sub.2 ; --NH--C.sub.1-6 alkyl; NH.sub.2 C (.dbd.NH--; NH.sub.2 C (.dbd.NH)--NH--; COOR.sub.31, wherein, R.sub.Type: GrantFiled: October 6, 1997Date of Patent: March 7, 2000Assignee: Astra ABInventors: John DiMaio, Wuyi Wang
-
Patent number: 5990104Abstract: Polycyclic alkaloids of formula (I), wherein R.sub.1 is H, C.sub.1-6 alkyl, or C.sub.6-12 aryl optionally substituted with polar groups; R.sub.2 and R.sub.3 are independently H, OH, C.sub.1-6 alkyl, --C(NH)--NH.sub.2, a positively charged group, or C.sub.7-13 aralkyl optionally substituted with NH.sub.2, OH, C.sub.1-6 alkyl, or halogen; or R.sub.2 and R.sub.3 together form a 5 to 6 member ring optionally incorporating a heteroatom; R.sub.4 is H, C.sub.1-6 alkyl, OR.sub.6, SR.sub.6, or N(R.sub.6).sub.2, wherein each R.sub.6 is independently H, C.sub.1-3 alkyl; X ix O, S, SO, SO.sub.2, or N--R.sub.5, wherein each R.sub.5 is independently H, C.sub.1-6 alkyl, or C.sub.7-13 aralkyl optionally interrupted with one or more heteroatom; n is an integer from 0 to 2; and m is an integer from 0 to 3. These compounds act as antagonists at the ionotropic NMDA (N-methyl-(D)-aspartic acid) receptor.Type: GrantFiled: March 25, 1998Date of Patent: November 23, 1999Assignee: Biochem Pharma, Inc.Inventors: John Dimaio, Dilip M. Dixit
-
Patent number: 5502036Abstract: Disclosed herein are pentapeptide derivatives of the formula X--NR.sup.1 --CH(R.sup.2)--C(W)--NH--CR.sup.3 (R.sup.4)--C(W.sup.2)--NR.sup.5 --CH CH.sub.2 C(O)--Y!--C(W.sup.3)--NH--CR.sup.6 -- CR.sup.7 (R.sup.8)--COOH!--C(W.sup.4)--NH--CR.sup.9 (R.sup.10)--Z wherein X is a terminal group, for example, alkanoyl or phenylalkanoyl radicals, R.sup.1 is hydrogen, alkyl or phenylalkyl, R.sup.2, R.sup.4 and R.sup.10 are selected from amino acid or derived amino acid residues, R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are hydrogen or alkyl or R.sup.7 and R.sup.8 are joined to form a cycloalkyl, W.sup.1, W.sup.2, W.sup.3 and W.sup.4 are oxo or thioxo, Y is, for example, an alkoxy or a mono or disubstituted amino, and Z is a terminal group, for example, COOH or CH.sub.2 OH. The derivatives are useful for treating herpes infections.Type: GrantFiled: March 9, 1994Date of Patent: March 26, 1996Assignee: BioMega Boehringer Ingelheim Research Inc.Inventors: Julian Adams, Pierre L. Beaulieu, Robert De/ ziel, John DiMaio, Louis Grenier, Pierre Lavalle/ e, Neil Moss
-
Patent number: 5258493Abstract: Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.Type: GrantFiled: March 16, 1992Date of Patent: November 2, 1993Assignee: Bio-Mega/Boehringer Ingelheim Research Inc.Inventors: Julian Adams, John DiMaio, Raymond Plante
-
Patent number: 5149778Abstract: Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.Type: GrantFiled: July 3, 1990Date of Patent: September 22, 1992Assignee: Bio-Mega, Inc.Inventors: Julian Adams, John DiMaio, Raymond Plante
-
Patent number: 4891358Abstract: Disclosed herein are derivatives of atrial natriuretic peptides wherein the exocyclic N-terminal peptide segment is deleted and the two cysteinyl residues (at positions 105 and 121) of the natural sequence are replaced with a trivalent unit, --NHCH(CO--)--Q--X--Y--CH.sub.2 CH.sub.2 CO-- wherein Q is methylene, ethylene or CR'R" wherein R' and R" each independently is lower alkyl, X is oxy or thio, and Y is methylene or des-Y. The derivatives may be optionally substituted at various positions including positions 106, 107 and 124. The derivatives possess ANF-like activity and are indicated for treating hypertension and for treating pathological conditions resulting from an imbalance of body fluids and electrolytes.Type: GrantFiled: December 15, 1988Date of Patent: January 2, 1990Assignee: Bio-Mega Inc.Inventors: John DiMaio, Dominik M. Wernic, Jorge Jaramillo